Mucosal eosinophilia and response to H1/H2 antagonist and cromolyn therapy in pediatric dyspepsia.
Both eosinophils and mast cells have been implicated in the generation of abdominal pain. The purposes of this retrospective study were to determine the prevalence of duodenal eosinophilia in pediatric dyspepsia and to determine the clinical response rate of these patients to combined H1 and H2 receptor antagonist and mast cell stabilizer therapy. Fifty-nine patients (ages 3.5-17.7 years) with dyspepsia undergoing endoscopy were evaluated. All patients had a minimum of 2 forceps biopsies obtained from each of the esophagus, antrum, and duodenal bulb. Routine histologic evaluation was performed and duodenal biopsies were additionally evaluated to determine eosinophil counts. Patients with > 10 eosinophils/hpf were treated with ranitidine and hydroxyzine (H1/H2). Nonresponders were then treated with oral cromolyn. Patients were followed up and response recorded in an abdominal pain database and/or medical chart, which were reviewed for this study. Forty-two patients (71%) had duodenal eosinophilia. Twenty-one (50%) of these were responders to H1/H2. The response rate did not differ between patients with and without noneosinophilic esophagitis, gastritis, or duodenitis, respectively. Two patients were lost to follow-up and considered nonresponders. Seventeen of the remaining 19 (89%) were responders to cromolyn. Overall, the response rate to this treatment pathway was 90%. Duodenal eosinophilia is common in pediatric patients with dyspepsia. These patients appear to be clinically amenable to combination H1/H2 therapy and/or oral cromolyn.
Friesen
Craig A
CA
Section of Gastroenterology, The Children's Mercy Hospital and Clinics, 2401 Gilham Road, Kansas City, MO 64108, USA.
Sandridge
Linda
L
Andre
Linda
L
Roberts
Charles C
CC
Abdel-Rahman
Susan M
SM
D015746:Abdominal Pain / Q000209:etiology; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004205:Cromolyn Sodium / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004386:Duodenum / Q000473:pathology; D004415:Dyspepsia / Q000188:drug therapy* / Q000209:etiology; D004802:Eosinophilia / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006633:Histamine Antagonists / Q000627:therapeutic use*; D006801:Humans; D006919:Hydroxyzine / Q000627:therapeutic use; D007413:Intestinal Mucosa / Q000473:pathology; D008407:Mast Cells / Q000187:drug effects; D011899:Ranitidine / Q000627:therapeutic use; D016896:Treatment Outcome
D006633:Histamine Antagonists; D006919:Hydroxyzine; D011899:Ranitidine; D004205:Cromolyn Sodium